Correlation Between Atrys Health and Oryzon Genomics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Atrys Health and Oryzon Genomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Atrys Health and Oryzon Genomics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Atrys Health SL and Oryzon Genomics SA, you can compare the effects of market volatilities on Atrys Health and Oryzon Genomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Atrys Health with a short position of Oryzon Genomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Atrys Health and Oryzon Genomics.

Diversification Opportunities for Atrys Health and Oryzon Genomics

-0.72
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Atrys and Oryzon is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Atrys Health SL and Oryzon Genomics SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oryzon Genomics SA and Atrys Health is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Atrys Health SL are associated (or correlated) with Oryzon Genomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oryzon Genomics SA has no effect on the direction of Atrys Health i.e., Atrys Health and Oryzon Genomics go up and down completely randomly.

Pair Corralation between Atrys Health and Oryzon Genomics

Assuming the 90 days trading horizon Atrys Health SL is expected to under-perform the Oryzon Genomics. But the stock apears to be less risky and, when comparing its historical volatility, Atrys Health SL is 3.32 times less risky than Oryzon Genomics. The stock trades about -0.11 of its potential returns per unit of risk. The Oryzon Genomics SA is currently generating about 0.23 of returns per unit of risk over similar time horizon. If you would invest  143.00  in Oryzon Genomics SA on December 29, 2024 and sell it today you would earn a total of  183.00  from holding Oryzon Genomics SA or generate 127.97% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy98.46%
ValuesDaily Returns

Atrys Health SL  vs.  Oryzon Genomics SA

 Performance 
       Timeline  
Atrys Health SL 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Atrys Health SL has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Oryzon Genomics SA 

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Oryzon Genomics SA are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Oryzon Genomics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Atrys Health and Oryzon Genomics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Atrys Health and Oryzon Genomics

The main advantage of trading using opposite Atrys Health and Oryzon Genomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Atrys Health position performs unexpectedly, Oryzon Genomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oryzon Genomics will offset losses from the drop in Oryzon Genomics' long position.
The idea behind Atrys Health SL and Oryzon Genomics SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
CEOs Directory
Screen CEOs from public companies around the world
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital